Don’t forget about tau: the effects of ApoE4 genotype on Alzheimer’s disease cerebrospinal fluid biomarkers in subjects with mild cognitive impairment—data from the Dementia Competence Network
Authors:
- Gloria S. BensonGBGloria S. Benson
- Chris BauerCBChris Bauer
- Lucrezia HausnerLHLucrezia Hausner
- Samuel CouturierSCSamuel Couturier
- Piotr LewczukPLPiotr Lewczuk
- Oliver PetersOPOliver Peters
- Michael HüllMHMichael Hüll
- Holger JahnHJHolger Jahn
- Frank JessenFJFrank Jessen
- Johannes PantelJPJohannes Pantel
- Stefan J. TeipelSTStefan J. Teipel
- Michael WagnerMWMichael Wagner
Open Access
- 21 January 2022
- journal article
- research article
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 129 (5-6) , 477-486
Abstract
ApoE4, the strongest genetic risk factor for Alzheimer’s disease (AD), has been shown to be associated with both beta-amyloid (Aβ) and tau pathology, with the strongest evidence for effects on Aβ, while the association between ApoE4 and tau pathology remains inconsistent. This study aimed to investigate the associations between ApoE4 with CSF Aβ42, total tau (t-tau), phospho-tau181 (p-tau), and with the progression of decline in a large cohort of MCI subjects, both progressors to AD and other dementias, as well as non-progressors. We analyzed associations of CSF Aβ42, p-tau and t-tau with ApoE4 allele frequency cross-sectionally and longitudinally over 3 years of follow-up in 195 individuals with a diagnosis of MCI-stable, MCI-AD converters and MCI progressing to other dementias from the German Dementia Competence Network. In the total sample, ApoE4 carriers had lower concentrations of CSF Aβ42, and increased concentrations of t-tau and p-tau compared to non-carriers in a gene dose-dependent manner. Comparisons of these associations stratified by MCI-progression groups showed a significant influence of ApoE4 carriership and diagnostic group on all CSF biomarker levels. The effect of ApoE4 was present in MCI-stable individuals but not in the other groups, with ApoE4 + carriers having decreased CSF Aβ 42 levels, and increased concentration of t-tau and p-tau. Longitudinally, individuals with abnormal t-tau and Aβ42 had a more rapid progression of cognitive and clinical decline, independently of ApoE4 genotype. Overall, our results contribute to an emerging framework in which ApoE4 involves mechanisms associated with both CSF amyloid-β burden and tau aggregation at specific time points in AD pathogenesis.Keywords
Funding Information
- Bundesministerium für Forschung, Technologie und Raumfahrt (01G10420)
- Ruprecht-Karls-Universität Heidelberg
This publication has 41 references indexed in Scilit:
- Spatial navigational strategies correlate with gray matter in the hippocampus of healthy older adults tested in a virtual mazeFrontiers in Aging Neuroscience, 2013
- Injury markers predict time to dementia in subjects with MCI and amyloid pathologyNeurology, 2012
- Apolipoprotein E and Apolipoprotein E Receptors: Normal Biology and Roles in Alzheimer DiseaseCold Spring Harbor Perspectives in Medicine, 2012
- Apolipoprotein E in Alzheimer's disease and other neurological disordersThe Lancet Neurology, 2011
- Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer diseaseAnnals of Neurology, 2010
- APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal agingAnnals of Neurology, 2010
- Early and Differential Diagnosis of Dementia and Mild Cognitive ImpairmentDementia and Geriatric Cognitive Disorders, 2009
- Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset FamiliesScience, 1993
- A New Depression Scale Designed to be Sensitive to ChangeThe British Journal of Psychiatry, 1979
- “Mini-mental state”Journal of Psychiatric Research, 1975